NCT00408304|UnknownPhase 2
Loading search results
Sponsor study identifier
interventional
60
1 country
1
Study Start
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
December 2007
Date type not reportedThis date has not been verified as actual or estimated.
The purpose of the study is to check whether development of depression as a side effect of interferon alpha treatment in chronic carriers of hepatitis C can be prevented by omega-3 fatty acids.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2007
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
December 5, 2006
Actual (reported)December 6, 2006
Actual (reported)December 2007
Date type not reportedThis date has not been verified as actual or estimated.
The effect of omega three fatty acids would be estimated through two questionnaires which filled by the patients monthly
with the BDI questionnaire which estimates the level of depression of the patient and
the SF36 questionnaire which provides information about the overall influence of a disease upon a patient's daily life and mental status.
Secondary outcome measures include monthly results of biochemical and hematologic blood tests, including levels of:
albumin
bilirubin
ALT
CRP
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Bnai Zion Medical Center
Haifa, Israel
Elad Schiff, MD
affiliated with Bnai Zion MC
First Submitted
December 5, 2006
First Posted
December 6, 2006
Study Start
December 2006
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
December 2007
Date type not reportedA Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C
Contact the study team to confirm eligibility.
This date has not been verified as actual or estimated.
Last Updated
December 6, 2006
Record last verified: 2006-12
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: